 |
|
|
| |
No Difference in Safety Profiles Comparing 12- and 24-Week HCV Treatment Durations in HCV Genotype 1 and HIV-1 Co-Infected
Patients: Results From TURQUOISE-I
|
| |
| |
Reported by Jules Levin
8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2015, Vancouver, British Columbia, Canada
Joseph J Eron1, Jihad Slim2, Richard Elion3, Ronald D'Amico4, Roger Trinh4, Yiran B Hu4, Melannie Co4, David Wyles5
1University of North Carolina, Chapel Hill, North Carolina, United States; 2St Michael's Medical Center, Newark, New Jersey, United States; 3Whitman-Walker Health, Washington, DC, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5University of California San Diego, La Jolla, California, United States
CROI/2015: HIGH SVR REGARDLESS OF TIME TO SUPPRESSION WITH OMBITASVIR/PARITAPREVIR/R & DASABUVIR + RBV - (03/02/15)
AASLD/2014: TURQUOISE-II: REGIMENS OF ABT-450/r/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVE HIGH SVR12 RATES IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS, REGARDLESS OF BASELINE CHARACTERISTICS.....http://www.natap.org/2014/AASLD/AASLD_03.htm
NEJM TURQUOISE-2 published April 2014 - ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis - Phase 3 TURQUOISE-II - (04/14/14)
|
| |
|
|
|
|
|
